Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold earlier this year, Lilly has transcended the traditional boundaries of a "Big Pharma" company to become a high-growth technology-like play on human longevity and [...]
As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition phase and inflation proving stickier than many had hoped, Wall Street is dusting off the playbook from the 2022
NEW YORK — In a stunning reversal of the "higher-for-longer" narrative that dominated much of 2025, the Bureau of Labor Statistics released its November Consumer Price Index (CPI) report today, December 18, 2025, showing inflation has cooled to a surprising 2.7% year-over-year. The figure, which came in well below the
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the efficacy of its daily oral pill, orforglipron.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall Street's expectations. The announcement immediately sent shockwaves through the market, with Pfizer's stock experiencing a notable decline as investors
Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and suggesting that still-higher prices for American equities may be on the horizon. While the Cboe Volatility Index (VIX) saw
